Among morbidly obese patients, apixaban was associated with a significantly lower risk of recurrent VTE, MB, and CRNM bleeding compared with warfarin
  Warfarin Apixaban   HR (95% CI) P value
No. of
events		 IR per 100
person-years		 No. of
events		 IR per 100
person-years
Recurrent VTE 337 8.0 130 5.4
 
 0.65 (0.53-0.80) <.001
Major bleeding 268 6.3 107 4.4
 
 0.68 (0.54-0.86) .001
GI bleeding 141 3.3 64 2.6
 
 0.78 (0.57-1.06) .114
Intracranial bleeding 17 0.4 <11 -
 
 0.10 (0.01-0.72) .023
Other major bleeding 122 2.9 45 1.9
 
 0.63 (0.44-0.90) .011
CRNM bleeding 1495 38.2 672 29.3
 
 0.76 (0.69-0.83) <.001
GI CRNM bleeding 360 8.6 200 8.4
 
 0.95 (0.79-1.14) .581
Other CRNM bleeding 1180 29.6 491 21.1
 
 0.70 (0.63-0.78) <.001
0
0.5
1
Favors apixaban
Favors warfarin
1|2|3